Latest1 information on COVID-19

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Not Recruiting

Trial ID: NCT00375830

Age - 18 Years-N/A Condition - Breast Cancer, Lung Cancer, Prostate Cancer, Breast - Early Stage, Breast - Metastatic / Advanced, Lung - Non-Small Cell (NSCLC), Lung - Small Cell Cancer (SCLC), Prostate - Localized, Prostate - Metastatic Gender - All Accepting Healthy Volunteers - No

Purpose

This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

Official Title

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Stanford Investigator(s)

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)

Sanjiv Sam Gambhir, MD, PhD

Robert Herfkens
Robert Herfkens

Professor of Radiology (Cardiovascular Imaging), Emeritus

Shreyas Vasanawala, MD/PhD
Shreyas Vasanawala, MD/PhD

William R. Brody Professor of Pediatric Radiology and Child Health

Eligibility


All patients were enrolled after receiving a regular medical care bone scan using the
radiolabel 99mTc-methyl diphosphonate (t99-MDP).

INCLUSION CRITERIA

   - ≥ 18 years old at the time of the drug administration

   - ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen
   (PSA) > 10 micrograms/L OR recurrent breast or prostate cancer

   - Capable of complying with study procedures

   - Able to remain still for duration of imaging procedure (about one hour)

   - Written informed consent

EXCLUSION CRITERIA

   - Pregnant or nursing

   - Metallic implants that contraindicate MRI

   - Renal function impairment that contraindicates MRI

View More
View Less

Intervention(s):

drug: Gadopentetate dimeglumine

drug: Gadofosveset

drug: Gadobutrol

procedure: Bone scan

procedure: Positron Emission Tomography (PET) scan

drug: 18F-Fludeoxyglucose (18F-FDG)

procedure: Computed Tomography (CT) scan

drug: 18F-Sodium Fluoride (18F-NaF)

procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan

drug: 99mTc-methyl diphosphonate

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine